- Home
- SDGR vs NEO Comparison
SDGR vs NEO Comparison
Compare SDGR & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SDGR | NEO |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | SDGR | NEO |
|---|---|---|
| Price | $17.53 | $11.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $26.25 | $12.56 |
| AVG Volume (30 Days) | 838.0K | ★ 1.7M |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $256,951,000.00 | ★ $709,162,000.00 |
| Revenue This Year | $23.69 | $10.90 |
| Revenue Next Year | $20.46 | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.90 | 10.10 |
| 52 Week Low | $15.99 | $4.72 |
| 52 Week High | $28.47 | $19.12 |
Technical Indicators
Market Signals| Indicator | SDGR | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 52.87 |
| Support Level | $17.53 | $11.59 |
| Resistance Level | $19.04 | $12.19 |
| Average True Range (ATR) | 0.74 | 0.38 |
| MACD | 0.12 | -0.11 |
| Stochastic Oscillator | 24.77 | 8.13 |
Price Performance
Historical ComparisonAbout SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.